Results
|
1.
|
Potential use of recombinant human thyrotropin in the treatment of distant metastases in patients with differentiated thyroid cancer. [Review] MedStar authors:
- Burman, Kenneth D
- Klubo-Gwiezdzinska, Joanna
- Mete, Mihriye
- Van Nostrand, Douglas
- Wartofsky, Leonard
Year: 2013
Citation: - Endocrine Practice. 19(1):139-48, 2013 Jan-Feb.
Institution:
- MedStar Health Research Institute
- MedStar Washington Hospital Center
Department:
- Medicine/Endocrinology
- Medicine/Nuclear Medicine
Medline publication type:
All authors: - Burman KD, Jonklaas J, Klubo-Gwiezdzinska J, Mete M, Van Nostrand D, Wartofsky L
|
|
2.
|
Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in the identification of metastasis in differentiated thyroid cancer with 131I planar whole-body imaging and 124I PET.[Erratum appears in J Nucl Med. 2012 May;53(5):830] MedStar authors:
- Atkins, Frank B
- Burman, Kenneth D
- Chennupati, Shyam P
- Kharazi, Pejman
- Khorjekar, Gauri R
- Mete, Mihriye
- Moreau, Shari
- O'Neil, Jeff
- Van Nostrand, Douglas
- Wartofsky, Leonard
Year: 2012
Citation: - Journal of Nuclear Medicine. 53(3):359-62, 2012 Mar.
Institution:
- MedStar Health Research Institute
- MedStar Washington Hospital Center
Department:
- Medicine/Endocrinology
- Medicine/Nuclear Medicine
Medline publication type:
- Journal Article
- Research Support, Non-U.S. Gov't
All authors: - Atkins FB, Burman KD, Chennupati SP, Kharazi P, Khorjekar GR, Mete M, Moreau S, O'Neil J, Van Nostrand D, Wartofsky L
|
|
3.
|
Treatment of HER2-positive metastatic breast cancer. MedStar authors:
Year: 2015
Citation: - New England Journal of Medicine. 372(20):1964-5, 2015 May 14.
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Baselga J, Clark E, Swain SM
|
|
4.
|
|
|
5.
|
|
|
6.
|
|
|
7.
|
<sup>18</sup>F-FDG-PET SUV AS A PROGNOSTIC MARKER OF INCREASING SIZE IN THYROID CANCER TUMORS. MedStar authors:
- Bikas, Athanasios
- Burman, Kenneth D
- Desale, Sameer
- Garcia, Carlos
- Singh, Ishita
- Wartofsky, Leonard
Year: 2017
Citation: - Endocrine Practice. 23(2):182-189, 2017 Feb
Institution:
- MedStar Heart & Vascular Institute
- MedStar Washington Hospital Center
- MedStar Washington Hospital Center
Department:
- Medicine/Endocrinology
- Medicine/Nuclear Medicine
Medline publication type:
All authors: - Bikas A, Burman KD, Desale S, Garcia CA, Singh I, Wartofsky L
|
|
8.
|
Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin. MedStar authors:
- Burman, Kenneth D
- Klubo-Gwiezdzinska, Joanna
- Mete, Mihriye
- Van Nostrand, Douglas
- Wartofsky, Leonard
Citation: - Thyroid. 22(3):310-7, 2012 Mar.
Institution:
- MedStar Health Research Institute
- MedStar Washington Hospital Center
Department:
- Medicine/Endocrinology
- Medicine/Nuclear Medicine
Medline publication type:
- Comparative Study
- Journal Article
All authors: - Burman KD, Jonklaas J, Klubo-Gwiezdzinska J, Mete M, Van Nostrand D, Wartofsky L
|
|
9.
|
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score >= 50. MedStar authors:
Year: 2021
Citation: - Journal of Clinical Oncology. 39(21):2339-2349, 2021 07 20.
Institution: - MedStar Franklin Square Medical Center
Medline publication type:
All authors: - Brahmer JR, Csoszi T, Cuffe S, Fulop A, Gottfried M, Hotta K, Hui R, Jensen E, Leal TA, O'Brien M, Peled N, Pietanza MC, Rao S, Reck M, Riess JW, Robinson AG, Rodriguez-Abreu D, Tafreshi A, Zhao B
|
|
10.
|
|
|
11.
|
Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA). MedStar authors:
Year: 2013
Citation: - Breast Cancer Research & Treatment. 142(1):89-99, 2013 Nov.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Amadori D, Baselga J, Clark E, Knott A, Miles D, Ross G, Semiglazov V, Sunpaweravong P, Swain SM
|
|
12.
|
Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. MedStar authors:
Year: 2013
Citation: - Oncologist. 18(3):257-64, 2013.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Amadori D, Baselga J, Benyunes MC, Clark E, Cortes J, Ewer MS, Knott A, Miles D, Ross G, Swain SM
|
|
13.
|
The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. MedStar authors:
Year: 2014
Citation: - BMC Cancer. 14:307, 2014.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial
- Journal Article
- Research Support, Non-U.S. Gov't
All authors: - Beattie M, Hurvitz S, Jahanzeb M, Kaufman PA, Lai C, Masaquel A, Mason G, O'Shaughnessy J, Rugo HS, Swain S, Tripathy D, Yoo B
|
|
14.
|
Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. MedStar authors:
Year: 2014
Citation: - Journal of Clinical Oncology. 32(33):3753-61, 2014 Nov 20.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Baselga J, Clark E, Cortes J, Im SA, Kiermaier A, Ross G, Swain SM
|
|
15.
|
SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. MedStar authors:
Year: 2019
Citation: - Journal of Translational Medicine. 17(1):429, 2019 12 26.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Baste N, Clayburgh D, Cohen EEW, Fountzilas G, Fujii T, Khaliq A, Kim ES, Lin D, Lipworth L, Mehlhorn H, Melillo G, Pai SI, Resteghini C, Shara N, Shire N, Stokes M, Twumasi-Ankrah P, Wang H, Wildsmith S, Zhang J
|
|
16.
|
Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. MedStar authors:
Year: 2013
Citation: - Annals of Oncology. 24(10):2630-5, 2013 Oct.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Baselga J, Clark E, Cortes J, Im SA, Im YH, Knott A, Pivot X, Ross G, Swain SM
|
|
17.
|
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. MedStar authors:
Year: 2015
Citation: - New England Journal of Medicine. 372(8):724-34, 2015 Feb 19.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Baselga J, Benyunes MC, Campone M, Ciruelos E, Clark E, CLEOPATRA Study Group, Cortes J, Ferrero JM, Heeson S, Kim SB, Ro J, Ross G, Schneeweiss A, Semiglazov V, Swain SM
|
|
18.
|
Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel. MedStar authors:
Year: 2013
Citation: - Anti-Cancer Drugs. 24(10):1084-92, 2013 Nov.
Institution: - Washington Cancer Institute
Medline publication type:
- Journal Article
- Research Support, Non-U.S. Gov't
All authors: - Baselga J, Brewster M, Cortes J, Garg A, Grincuka E, Hauschild M, Kudaba I, Lum BL, Marier JF, Masuda N, McNally V, Nijem I, Patel T, Ross G, Swain SM, Trinh MM, Visich J
|